NL201 / Beijing Northland - LARVOL DELTA

NL-201 in Patients With Relapsed or Refractory Cancer (clinicaltrials.gov) - P1; N=120; Not yet recruiting; Sponsor: Neoleukin Therapeutics, Inc.

Clinical • New P1 trial • Oncology • Solid Tumor

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 (clinicaltrials.gov) - P3; N=62; Completed; Sponsor: Beijing Northland Biotech. Co., Ltd.; Active, not recruiting ➔ Completed; N=300 ➔ 62

Clinical • Enrollment change • Trial completion • Hematological Disorders • Oncology • Thrombocytopenia

Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement (GlobeNewswire, Aquinox Pharmaceuticals, Inc.) - • Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable therapeutic index. Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP) and Neoleukin Therapeutics, Inc. (“Neoleukin”), a privately held biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition of Neoleukin, which is expected to close on or about August 8th, 2019. Pursuant to the merger agreement, Aquinox will acquire all of the outstanding capital stock of Neoleukin in exchange for a combination of common and preferred shares. In connection with the merger, Aquinox will be renamed as Neoleukin Therapeutics, Inc., and is expected to trade on the Nasdaq Global Market under the new ticker symbol “NLTX”, concurrent with closing.Neoleukin’s lead product candidate, NL-201, is a de novo protein designed to mimic the...

Clinical • Commercial